GW Pharmaceuticals has confirmed that the European Commission (EC) has approved Epidyolex® (cannabidiol) as an adjunctive treatment for TSC-related epilepsy in people aged two years and older. The approval marks an important stepping stone in the journey towards the eventual approval and access to